Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial.

Tufia C Haddad Vera J Suman Karthik V Giridhar Kostandinos Sideras Donald W Northfelt Brenda J Ernst Ciara Catherine O'Sullivan Ravinder J Singh Zeruesenay Desta Prema P Peethambaram Timothy J Hobday Saranya Chumsri Roberto A Leon-Ferre Kathryn J Ruddy Siddhartha Yadav Jodi L Taraba Barbara Goodnature Matthew P Goetz Liewei Wang James N Ingle

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Approximately 30% of ANA1-adherent patients had IES. Among those who switched to ANA10 and were adherent, 76% had AES. Further studies are required to validate emerging data that ANA1 results in IES for some patients and to determine the clinical benefit of switching to ANA10 or an alternative AI.

Keyphrases

early stage
newly diagnosed
ejection fraction
artificial intelligence
patient reported outcomes
young adults
patient reported
open label
big data
deep learning